Recruiting

Endothelial Derived Hyperpolarization Factor

Sponsor:

University of Oklahoma

Code:

NCT05176379

Conditions

Healthy

Eligibility Criteria

Sex: All

Age: 18 - 30

Healthy Volunteers: Accepted

Interventions

Fluconazole 150 mg

Study Details

Brief summary:

Most cardiometabolic diseases are characterized by increased muscle sympathetic nerve activity (MSNA) during rest and exercise which contributes to poor health outcomes. In healthy humans during muscle contraction, there is a blunting of skeletal muscle vascular responsiveness to increases in MSNA. However, the exact mechanisms involved are unknown although, best evidence suggests that the mechanism is endothelium derived, but nitric oxide (NO) and prostaglandin (PG) independent. Endothelium-derived hyperpolarizing factor (EDHF) is a NO and PG independent vasodilator in both cerebral and skeletal muscle circulations, however, it is unknown if EDHF contributes to vascular responsiveness during elevated MSNA. The application of lower body negative pressure (LBNP) is a safe and non-invasive manipulation that can be used to increase MSNA causing vasoconstriction in humans. Therefore, the purpose of this experiment is to determine if acute inhibition of EDHF alters central and peripheral vascular responses to LBNP at rest and during dynamic exercise. Thereby, providing evidence by which EDHF contributes to vascular control in healthy humans and identify it's potential as a therapeutic target for cardiometabolic diseases that are characterized by elevated MSNA

Conditions

Healthy

Study ID

NCT05176379

Start date

Feb 19, 2022

Status verified date

Jul, 2024

Completion date

May, 2025

Anticipated

Primary completion date

Dec, 2024

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 30

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Normotensive (systolic blood pressure < 130 mmHg and/or diastolic blood pressure < 85 mmHg) individuals
  • Individuals free of cardiovascular disease and metabolic disease
  • Individuals free of any form of autonomic dysfunction
  • Individuals with a BMI under 30 kg/m²
  • Women that are premenopausal with a regular menstrual cycle (26-30 days)

Exclusion Criteria:

  • Smokers, tobacco users (regular use in the last 6 months)
  • Individuals with a blood pressure greater than 130/85
  • Subjects who use Amiodarone, Sulphaphenazole
  • Subjects who use S-warfarin, Tolbutamine, Phenytoin, Lonafarnib
  • Cardiometabolic medication use (e.g. anti-hypertensives, insulin-sensitizing, statins)
  • Sex hormone replacement medical use (e.g. testosterone, estrogen, progesterone)
  • Pregnancy

Study Design

Enrollment

30 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: fluconazole

fluconazole tablet/pill 150 mg, single acute dose

placebo comparator: Placebo

250 mg pill microcrystalline Cellulose, single acute dose

Interventions

Fluconazole 150 mg

A single acute 150 mg dose

Primary outcome measure

  • Near-Infrared Spectroscopy [ Time Frame: up to 4 hours ]
  • Transcranial Doppler Ultrasound [ Time Frame: up to 4 hours ]

Central Contacts and Locations

Central contacts

Jeremy M Kellawan, PhD

4053259028kellawan@ou.edu

Locations

Department of Health and Exercise Science

Recruiting

Norman, Oklahoma, United States, 73019

Contacts

Michael Bemben, PhD

405-325-5211mgbemben@ou.edu

Jeremy M Kellawan, PhD

(405) 325-9028kellawan@ou.edu

Principal Investigator:

Jeremy M Kellawan, PhD

More Information

Sponsor

University of Oklahoma

Last update posted

Jul 23, 2024

Last verified

Jul, 2024

Keywords

  • brain blood flow
  • muscle blood flow
  • endothelial function

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Oklahoma on 2024-07-23.